海欣股份：子公司药品通过仿制药一致性评价

Core Viewpoint - The company announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] - The "Vitamin B6 Injection" is now positioned to enter the market, potentially increasing the company's revenue streams [1] - The successful completion of the consistency evaluation indicates the company's commitment to maintaining high-quality standards in its pharmaceutical offerings [1]